Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III

Executive Summary

Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.

Advertisement

Related Content

Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Cytokinetics Seeks ALS Success By Focusing On Lung Function
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Cytokinetics Awaits Amgen's Phase III Plan After Phase II Heart Drug Success
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Amgen, Cytokinetics' heart drug misses goal in Phase II study

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097235

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel